Ethos Technologies Inc. (LIFE) Q4 2022 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon, ladies and gentlemen, and welcome to the 8th Tower Farmer fourth quarter and full year 2022 conference call. At this time, all participants are on a listen-only mode. Later, we'll conduct a question and answer session, and instructions will be given at that time. As a reminder, this conference call is being recorded for replay purposes. It is now my pleasure to hand the conference over to Ashley Dunstan, 8th Tower's Director of Investor Relations and Corporate Communications. Ms. Dunstan, you may begin. Thank you, and good afternoon, everyone. Thank you for joining us today to discuss ATIRE's fourth quarter and full year 2022 operating results and corporate update. We are joined today by Dr. Sanjay Shukla, our president and CEO, and Ms. Jill Broadfoot, our CFO. On the call, Sanjay will provide an update on our corporate strategy, including our clinical program for EpsoCitimod and research and discovery programs. Jill will review the financial results and our current financial position before handing it back to Sanjay to open the call for any questions. Before we begin, I would like to remind everyone that except for statements of historical facts, the statements made by management and responses to questions on this conference call are forward-looking statements under the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that can cause actual results to differ materially from those and such forward-looking statements. Please see the forward-looking statement disclaimer in the company's press release issued this afternoon as well as the risk factors in the company's SEC filings and included in our most recent annual report on Form 10-K, subsequently filed quarterly reports on ...